#United States #Spring House #Crohn's Disease #TREMFYA #guselkumab

TREMFYA® Demonstrates Promising Results for Perianal Fistulas in Crohn's Disease

In a significant advancement for treating Crohn's disease, Johnson & Johnson has unveiled new Phase 3 clinical trial results showcasing the efficacy of TREMFYA® (guselkumab) in achieving remission of perianal fistulas. The findings, presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, highlight consistent remission outcomes across critical patient subgroups, reinforcing the medication's role in managing this challenging condition.

Understanding Perianal Fistulas

Perianal fistulas are painful, often debilitating complications associated with Crohn's disease, affecting nearly 25% of patients. They result in drainage, pain, and recurrent infections, significantly impairing the quality of life and necessitating surgical interventions. Effective treatment options have been historically limited, making the recent findings particularly impactful.

Phase 3 Study Insights

The latest study builds upon previously reported positive results that indicated a combined fistula remission rate of 28% among patients receiving TREMFYA 100 mg every eight weeks and 27% for those on 200 mg every four weeks. In contrast, only 10% of patients taking a placebo experienced similar outcomes. This makes TREMFYA the only IL-23 inhibitor to demonstrate efficacy in a dedicated, randomized, placebo-controlled trial for this patient group.

Additional subgroup analyses indicated impressive results, showcasing higher remission rates for:

• - Patients showing greater luminal disease activity (CDAI ≥220) – 30% and 21% for TREMFYA 100 mg and 200 mg respectively, against 0% for placebo.
• - Patients with prior biologic exposure – 21% and 29% for TREMFYA compared to 5% for placebo.
• - Patients with proctitis at baseline, achieving remission rates of 26% and 27% against 12% for placebo.
• - Patients without proctitis, demonstrating 29% and 27% versus 10% for placebo.

Expert Commentary

Dr. Bruce Sands, a leading expert in gastroenterology and one of the study's contributors, emphasized the significance of these findings: "Perianal fistula remain one of the most debilitating manifestations of moderate to severe Crohn's disease, and many patients continue to experience persistent drainage, pain, and complications. These analyses demonstrate that TREMFYA's efficacy is consistent across diverse yet clinically relevant patient populations."

Meeting Patient Needs

The implications of TREMFYA's success highlight an important step in addressing the unmet needs of Crohn's disease patients suffering from perianal fistulas. According to David M. Lee, M.D., Ph.D., Global Immunology Therapeutic Area Head at Johnson & Johnson, the FUZION study was meticulously designed to create reliable evidence specifically tailored to understanding how TREMFYA can fill existing treatment gaps for these patients.

Product Overview

TREMFYA is a dual-acting monoclonal antibody, recognized for its ability to target and neutralize the inflammation caused by IL-23, a cytokine implicated in the progression of Crohn's disease. Approved for various indications, including moderate to severe active Crohn's disease, TREMFYA represents a promising frontier in inflammatory bowel disease treatment.

Conclusion

The recent Phase 3 FUZION study results present a breakthrough in Crohn's disease management, specifically for patients experiencing the debilitating impacts of perianal fistulas. As healthcare professionals and researchers continue to explore the potential of treatments like TREMFYA, patients can find hope in the effectiveness of these new therapeutic options in navigating their disease challenges. For further detailed insights and future updates, please visit the Johnson & Johnson website.